Our aim
We aim to optimize the CRISPR-Cas gene editing technology as a gene therapy in these diseases, and stratify the existing therapies – such as biologic drugs and small molecule inhibitors – to better target the underlying molecular pathways that malfunction in individual patients.
Our methods
We utilize custom genomics methods and high-throughput screening to understand immune diseases and optimize CRISPR-Cas9 genome editing towards safe and efficient use in patients. We work with cell models and patient material, and strive to create teams with diverse expertise in molecular and computational biology and clinical medicine.